Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis
Highlight
- In patients with established coronary artery disease (CAD), clopidogrel monotherapy significantly reduces major adverse cardiovascular or cerebrovascular events (MACCE) compared to aspirin.
- No significant difference in major bleeding or mortality was observed between clopidogrel and aspirin monotherapy during long-term follow-up.
- This evidence supports preferential use of clopidogrel over aspirin as secondary prevention in CAD patients, especially those post-percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS).
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.